Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions

The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine...

Descripció completa

Dades bibliogràfiques
Autors principals: Jeffrey Vietri, James Harnett, Birol Emir, Erica Chilson
Format: Article
Idioma:English
Publicat: Taylor & Francis Group 2020-01-01
Col·lecció:Human Vaccines & Immunotherapeutics
Matèries:
13-valent pneumococcal vaccine
pneumococcal conjugate vaccine
pcv13
pneumococcal disease
pneumococcal vaccines
immunization
risk factors
Accés en línia:http://dx.doi.org/10.1080/21645515.2019.1632683

Internet

http://dx.doi.org/10.1080/21645515.2019.1632683

Ítems similars